Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:BYSI NASDAQ:FNCH NASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.81+1.0%$0.75$0.51▼$1.38$77.49M0.35173,397 shs143,737 shsBYSIBeyondSpring$1.82-2.7%$1.98$0.98▼$3.44$75.42M0.2226,656 shs9,682 shsFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsIRDOpus Genetics$1.38-2.1%$1.17$0.65▼$1.75$84.47M0.07213,599 shs324,888 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+1.01%+1.94%+0.12%+28.71%-35.96%BYSIBeyondSpring-2.67%-2.15%-9.00%-34.77%-15.74%FNCHFinch Therapeutics Group-2.13%-2.36%+2.06%-9.82%+5.53%IRDOpus Genetics-2.13%+8.66%+25.45%+42.27%+137,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.81+1.0%$0.75$0.51▼$1.38$77.49M0.35173,397 shs143,737 shsBYSIBeyondSpring$1.82-2.7%$1.98$0.98▼$3.44$75.42M0.2226,656 shs9,682 shsFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsIRDOpus Genetics$1.38-2.1%$1.17$0.65▼$1.75$84.47M0.07213,599 shs324,888 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+1.01%+1.94%+0.12%+28.71%-35.96%BYSIBeyondSpring-2.67%-2.15%-9.00%-34.77%-15.74%FNCHFinch Therapeutics Group-2.13%-2.36%+2.06%-9.82%+5.53%IRDOpus Genetics-2.13%+8.66%+25.45%+42.27%+137,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.33Hold$2.38192.02% UpsideBYSIBeyondSpring 0.00N/AN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/AIRDOpus Genetics 3.00Buy$7.33431.40% UpsideCurrent Analyst Ratings BreakdownLatest FNCH, IRD, BYSI, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.50 ➝ $3.006/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.63$0.05 per share16.40$1.27 per share0.64BYSIBeyondSpring$1.75M41.94N/AN/A($0.37) per share-4.92FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AIRDOpus Genetics$10.99M7.52N/AN/A$0.21 per share6.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A27.11N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/A11/6/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AIRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%11/11/2025 (Estimated)Latest FNCH, IRD, BYSI, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BYSIBeyondSpringN/A-$0.04N/A-$0.04N/AN/A8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34BYSIBeyondSpringN/A2.192.19FNCHFinch Therapeutics GroupN/A3.873.87IRDOpus Genetics0.061.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%BYSIBeyondSpring40.29%FNCHFinch Therapeutics Group21.77%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%BYSIBeyondSpring29.31%FNCHFinch Therapeutics Group44.90%IRDOpus Genetics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableBYSIBeyondSpring8040.33 million28.51 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataIRDOpus Genetics1459.91 million55.95 millionN/AFNCH, IRD, BYSI, and ASRT HeadlinesRecent News About These CompaniesOpus Genetics reports inducement grant under Nasdaq listing rulesSeptember 12 at 11:51 AM | msn.comOpus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 12 at 8:00 AM | globenewswire.comAWM Investment Company Inc. Acquires Shares of 524,245 Opus Genetics, Inc. $IRDSeptember 5, 2025 | marketbeat.comOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under ...September 4, 2025 | finance.yahoo.comOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsSeptember 4, 2025 | globenewswire.comOpus Genetics Appoints New Chief Financial OfficerSeptember 3, 2025 | msn.comOpus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comNantahala Capital Management LLC Purchases Shares of 3,157,895 Opus Genetics, Inc. $IRDSeptember 3, 2025 | marketbeat.comOpus Genetics Appoints Rob Gagnon as Chief Financial OfficerSeptember 2, 2025 | globenewswire.comBIOS Capital Management LP Invests $977,000 in Opus Genetics, Inc. $IRDAugust 28, 2025 | marketbeat.comOpus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in SeptemberAugust 27, 2025 | globenewswire.comMink Brook Asset Management LLC Acquires Shares of 810,080 Opus Genetics, Inc. $IRDAugust 26, 2025 | marketbeat.comFDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal diseaseAugust 20, 2025 | ophthalmologytimes.comOOpus Genetics, Inc.: Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1August 18, 2025 | finanznachrichten.deOpus Genetics announces FDA clearance of IND application for OPGx-BEST1August 18, 2025 | msn.comOpus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1August 18, 2025 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 16, 2025 | finance.yahoo.comOpus Genetics (NASDAQ:IRD) Issues Earnings ResultsAugust 15, 2025 | marketbeat.comOpus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14, 2025 | finance.yahoo.comOpus Genetics reports Q2 EPS (12c) vs (30c) last yearAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, IRD, BYSI, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$0.81 +0.01 (+1.01%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.81 0.00 (-0.41%) As of 09/12/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.BeyondSpring NASDAQ:BYSI$1.82 -0.05 (-2.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.81 -0.01 (-0.55%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Finch Therapeutics Group NASDAQ:FNCH$12.40 -0.27 (-2.13%) As of 09/12/2025 03:50 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Opus Genetics NASDAQ:IRD$1.38 -0.03 (-2.13%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.36 -0.01 (-1.09%) As of 09/12/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
